Correlation of serum IL-13 and IL-5 levels with clinical response to Glatiramer acetate in patients with multiple sclerosis

Clinical and Experimental Immunology

Volumn 133, Issue 3, 2003, Pages 454-460

  Wiesemann, E ^a   Klatt, J ^a   Wenzel, C ^a   Heidenreich, F ^a   Windhagen, A ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Glatirameracetate; IL 13; IL 5; Multiple sclerosis

Indexed keywords

GLATIRAMER; INTERLEUKIN 13; INTERLEUKIN 5;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREGULATION; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATIENT MONITORING; PRIORITY JOURNAL; T LYMPHOCYTE; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANALYSIS OF VARIANCE; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-13; INTERLEUKIN-5; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PEPTIDES; TREATMENT OUTCOME;

EID: 0042827531     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2003.02238.x     Document Type: Article

References (27)

1. Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45:1268-76.
2. Comi G, Filippi M, for the Copaxone MRI study group. The effect of glatiramer acetate (Copaxone) on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis (RRMS): a multicenter, randomized, double blind, placebo-controlled study extended by open-label treatment. Neurology 1999; 56 (Suppl. 2):289.
3. Johnson KP, Brooks BR, Ford CC et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 2000; 6:255-66.
4. Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001; 56:702-8.
5. Gran B, Tranquill L, Chen M et al. Mechanisms of immunomodulation by glatiramer acetate. Neurology 2001; 55:1704-14.
6. Brosnan CF, Litwak M, Neighbour PA et al. Immunogenic potentials of copolymer I in normal human lymphocytes. Neurology 1985; 35:1754-9.
7. Brenner T, Arnon R, Sela M et al. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol 2001; 115:152-60.
8. Farina C, Then BF, Albrecht H et al. Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. Brain 2001; 124:705-19.
9. Wiesemann E, Klatt J, Sonmez D, Blasczyk R, Heidenreich F, Windhagen A. Glatiramer acetate (GA) induces IL-13/IL-5 secretion in naive T cells. J Neuroimmunol 2001; 119:137-44.
10. Chen M, Gran B, Costello K, Johnson K, Martin R, Dhib-Jalbut S. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult Scler 2001; 7:209-19.
11. Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000; 105:967-76.
12. Miller A, Shapiro S, Gershtein R et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998; 92:113-21.
13. Neuhaus O, Farina C, Yassouridis A et al. Multiple sclerosis, comparison of copolymer-1-reactive T cells lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci USA 2000; 97:7452-7.
14. Farina C, Wagenpfeil S, Hohlfeld R. Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis A pilot study. J Neurol 2002; 249:1587-92.
15. Calopa M, Bas J, Mestre M, Arbizu T, Peres J, Buendia E. T cell subsets in multiple sclerosis: a serial study. Acta Neurol Scand 1995; 92:361-8.
16. Chofflon M, Weiner HL, Morimoto C, Hafler DA. Decrease of suppressor inducer (CD4+2H4+) T cells in multiple sclerosis cerebrospinal fluid. Ann Neurol 1989; 25:494-9.
17. Morimoto C, Hafler DA, Weiner HL et al. Selective loss of the suppressor-inducer T-cell subset in progressive multiple sclerosis. Analysis with anti-2H4 monoclonal antibody. N Engl J Med 1987; 316:67-72.
18. Qin Y, Zhang DQ, Prat A, Pouly S, Antel J. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients. J Neuroimmunol 2000; 108:201-6.
19. Windhagen A, Maniak S, Marckmann S, Lindert RB, Heidenreich F, Blasczyk R. Lymphadenopathy in patients with multiple sclerosis undergoing treatment with glatiramer acetate. J Neurol Neurosurg Psychiatry 2001; 70:415-6.
20. Windhagen A, Anderson DE, Carrizosa A, Balashov K, Weiner HL, Hafler DA. Cytokine secretion of myelin basic protein reactive T cells in patients with multiple sclerosis. J Neuroimmunol 1998; 91:1-9.
21. Kelly BL, Locksley RM. Coordinate regulation of the IL-4, IL-13, and IL-5 cytokine cluster in Th2 clones revealed by allelic expression patterns. J Immunol 2000; 165:2982-6.
22. Fallon PG, Jolin HE, Smith P et al. IL-4 Induces Characteristic Th2 Responses Even in the Combined Absence of IL-5, IL-9, and IL-13. Immunity 2002; 17:7-17.
23. Foster PS, Martinez-Moczygemba M, Huston DP, Corry DB. Interleukins-4-5, and - 13: emerging therapeutic targets in allergic disease. Pharmacol Ther 2002; 94:253-64.
24. de Vries JE. The role of IL-13 and its receptor in allergy and inflammatory responses. J Allergy Clin Immunol 1998; 102:165-9.
25. Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 1996; 183:195-201.
26. Lucchinetti CF, Mandler RN, McGavern D et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125:1450-61.
27. Wensky A, Marcondes MC, Lafaille JJ. The role of IFN-gamma in the production of Th2 subpopulations: implications for variable Th2-mediated pathologies in autoimmunity. J Immunol 2001; 167:3074-81.